Christoph Massner
Director/Board Member at Ariceum Therapeutics GmbH
Profile
Christoph Massner currently works at Ariceum Therapeutics GmbH, as Non-Executive Director and Earlybird Venture Capital GmbH & Co. KG, as Associate from 2020.
Christoph Massner active positions
Companies | Position | Start |
---|---|---|
Earlybird Venture Capital GmbH & Co. KG
Earlybird Venture Capital GmbH & Co. KG Investment ManagersFinance Earlybird Venture Capital GmbH & Co. KG (Earlybird VC) is an independent venture capital firm founded by Hendrik Brandis, Roland Manger, Rolf Mathies, and Christian Nagel in 1997. It is a wholly-owned subsidiary of Earlybird VC Management GmbH & Co. KG. The firm is headquartered in Munich, Germany, with another German office in Berlin, and international office in Istanbul, Turkey. | Private Equity Analyst | 30/04/2018 |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Earlybird Venture Capital GmbH & Co. KG
Earlybird Venture Capital GmbH & Co. KG Investment ManagersFinance Earlybird Venture Capital GmbH & Co. KG (Earlybird VC) is an independent venture capital firm founded by Hendrik Brandis, Roland Manger, Rolf Mathies, and Christian Nagel in 1997. It is a wholly-owned subsidiary of Earlybird VC Management GmbH & Co. KG. The firm is headquartered in Munich, Germany, with another German office in Berlin, and international office in Istanbul, Turkey. | Finance |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Commercial Services |
- Stock Market
- Insiders
- Christoph Massner